NIKKEI 225
38,648.39 -298.54 (-0.77%) HANG SENG
19,207.24 -13.38 (-0.07%) CRUDE OIL
79.06 -0.20 (-0.25%) GOLD FUTURES
2,423.20 -2.70 (-0.11%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
55,106.73 -786.65 (-1.41%)
Alnylam Pharmaceuticals, Inc. (ALNY)
After hours:
| Previous close | 150.24 |
| Open | 149.44 |
| Bid | 149.44 x 200 |
| Ask | 149.79 x 200 |
| Day's range | 147.89 - 151.45 |
| 52-week range | 141.98 - 218.88 |
| Volume | |
| Avg. volume | 607,125 |
| Market cap | 19.004B |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Alnylam Issues 2023 Corporate Responsibility Report
CAMBRIDGE, Mass., May 07, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2023 Corporate Responsibility Report. The company continues to take meaningful steps across each of its six corporate responsibility pillars. This year’s edition expands data disclosures across each pillar and highlights examples of the company’s commitment to ensuring patient access, reducing health inequities, and being a responsible stewar
- Business Wire
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
CAMBRIDGE, Mass., May 02, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights.
- PR Newswire
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a further expansion of their existing partnership in Central & Eastern Europe and Israel, to also include selected markets in LATAM and APAC and additional international markets.
